{
  "id": "56d04a533975bb303a000010",
  "type": "factoid",
  "question": "What is dovitinib?",
  "ideal_answer": "Dovitinib (TKI258) is a tyrosine kinase receptor inhibitor with potent activity against fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23228017",
    "http://www.ncbi.nlm.nih.gov/pubmed/24908540",
    "http://www.ncbi.nlm.nih.gov/pubmed/21521775",
    "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
    "http://www.ncbi.nlm.nih.gov/pubmed/24495750",
    "http://www.ncbi.nlm.nih.gov/pubmed/21976540",
    "http://www.ncbi.nlm.nih.gov/pubmed/25023489",
    "http://www.ncbi.nlm.nih.gov/pubmed/22180308",
    "http://www.ncbi.nlm.nih.gov/pubmed/24238094",
    "http://www.ncbi.nlm.nih.gov/pubmed/23010851",
    "http://www.ncbi.nlm.nih.gov/pubmed/23339124",
    "http://www.ncbi.nlm.nih.gov/pubmed/26070683",
    "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
    "http://www.ncbi.nlm.nih.gov/pubmed/23400739",
    "http://www.ncbi.nlm.nih.gov/pubmed/24448819",
    "http://www.ncbi.nlm.nih.gov/pubmed/22230479",
    "http://www.ncbi.nlm.nih.gov/pubmed/24556040"
  ],
  "snippets": [
    {
      "text": "This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a receptor tyrosine kinase inhibitor with potent activity against fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR), in locally advanced or metastatic thyroid cancer patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26070683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010851",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21976540",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23339124",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "tyrosine kinase receptor inhibitor"
}